Study wrapper · #471
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
Editor's note
This large Bayesian network meta-analysis pooled 102 randomised trials (98,693 people with type 2 diabetes) to compare 15 incretin-based therapies, including single, dual, and triple receptor agonists. Among tracked agents, tirzepatide and semaglutide ranked among the best for glycaemic control, and the authors reported that gastrointestinal adverse events were the most common and generally mild and transient, with low hypoglycaemia risk. Higher doses improved efficacy but increased side effects. The scale and low overall risk of bias make this a substantial synthesis, but network meta-analyses rest on indirect comparisons and SUCRA rankings that should not be over-interpreted as definitive head-to-head superiority. For semaglutide and tirzepatide readers, this reinforces their strong glycaemic positioning within the incretin class while underscoring the dose-tolerability trade-off. The authors call for long-term high-quality trials.
Plain-language abstract
Researchers combined 102 randomised trials covering nearly 99,000 people with type 2 diabetes to compare 15 incretin-based diabetes medicines. Tirzepatide and semaglutide were among the top performers for lowering blood sugar, and newer triple-action drugs led for weight loss. The most common side effects were mild, short-lived stomach and gut symptoms, and the risk of dangerously low blood sugar was low. Higher doses worked better but caused more side effects. The authors note that many comparisons between drugs were indirect, so the rankings should be read as guidance rather than proof that one drug beats another. Overall, semaglutide and tirzepatide stood out for blood-sugar control within this drug family.